1. Home
  2. TECX vs RLMD Comparison

TECX vs RLMD Comparison

Compare TECX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$21.01

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

319.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
RLMD
Founded
2019
2004
Country
United States
United States
Employees
51
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
319.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
TECX
RLMD
Price
$21.01
$4.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$80.40
$9.00
AVG Volume (30 Days)
529.5K
620.1K
Earning Date
01-01-0001
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.21
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$13.70
$0.24
52 Week High
$27.64
$5.12

Technical Indicators

Market Signals
Indicator
TECX
RLMD
Relative Strength Index (RSI) 48.41 52.15
Support Level $20.52 $3.81
Resistance Level $25.39 $4.56
Average True Range (ATR) 2.35 0.35
MACD -0.23 0.04
Stochastic Oscillator 45.94 68.39

Price Performance

Historical Comparison
TECX
RLMD

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: